What are Uricosuric enzyme drugs?

Uricosuric enzyme drugs are pharmacologic agents that share a common mechanism (typically targeting Uric acid). 5 are currently marketed, with 5 more in clinical development.

What are the marketed Uricosuric enzyme drugs?

Marketed Uricosuric enzyme drugs include urate oxidase, phenytoin and probenecid, olmesartan medoxomil+probenecid, Benzbromarone (drug), ULO.

Uricosuric enzyme

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

5 marketed 4 in Phase 3 1 in Phase 1

This page covers all Uricosuric enzyme drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Uric acid, Voltage-gated sodium channels (phenytoin); organic acid transporter (probenecid), AT1 receptor (angiotensin II type 1 receptor); uric acid transporter (URAT1).

Targets

Uric acid · Voltage-gated sodium channels (phenytoin); organic acid transporter (probenecid) · AT1 receptor (angiotensin II type 1 receptor); uric acid transporter (URAT1) · URAT1 (urate transporter 1) · AMPK (AMP-activated protein kinase) / Xanthine oxidase pathway · SARS-CoV-2 RNA-dependent RNA polymerase, Uric acid transporter

Marketed (5)

urate oxidase · Sanofi · Oncology; Rheumatology
Urate oxidase catalyzes the conversion of uric acid to allantoin, a more soluble compound that is readily excreted in urine.
phenytoin and probenecid · Jim McAuley · Neurology and Rheumatology
Phenytoin is an anticonvulsant that stabilizes neuronal membranes and reduces seizure activity, while probenecid is a uricosuric agent that increases uric acid excretion and can inhibit renal tubular secretion of certain drugs.
olmesartan medoxomil+probenecid · Central South University · Cardiovascular; Rheumatology
Olmesartan medoxomil blocks angiotensin II receptors to lower blood pressure, while probenecid inhibits uric acid reabsorption in the kidney to reduce serum uric acid levels.
Benzbromarone (drug) · Tottori University Hospital · Rheumatology
Benzbromarone inhibits renal urate reabsorption by blocking the urate transporter URAT1, thereby increasing urinary uric acid excretion and lowering serum uric acid levels.
ULO · Merck Sharp & Dohme LLC · Rheumatology; Gout
ULO is a uricosuric agent that increases urinary excretion of uric acid by inhibiting renal urate reabsorption.

Phase 3 pipeline (4)

Uritos® · R-Pharm · Rheumatology / Metabolic Disorders
Uritos is a uricosuric agent that increases urinary excretion of uric acid by inhibiting renal urate reabsorption.
Probenecid 500 Milligrams (mg) · University of Miami · Rheumatology
Probenecid inhibits the renal tubular reabsorption of uric acid, increasing urinary excretion and lowering serum uric acid levels.
Bempedoic Acid Tablet · Gan & Lee Pharmaceuticals. · Rheumatology / Metabolic Disease
Bempedoic acid inhibits AMPK-activated protein kinase to reduce uric acid production and lower serum uric acid levels.
probenecid 250 Milligrams (mg) · University of Miami · Rheumatology
Probenecid works by inhibiting the reabsorption of uric acid in the kidneys, thereby increasing its excretion in the urine.

Phase 1 pipeline (1)

AT-527 and Probenecid · Atea Pharmaceuticals, Inc. · Infectious Disease
AT-527 is a nucleoside analog that inhibits the RNA-dependent RNA polymerase of SARS-CoV-2, and Probenecid is a uricosuric agent that increases the renal excretion of uric acid.

Patent intelligence

uricosuric patent landscape — aggregated cliff calendar, attackable patents, originator estates